Regarding the methylation status of the promoter of the MGMT gene (O6-methylguanine-DNA-methyltransferase, a known predictive factor of response to temozolomide in adult-type gliomas [56]), few cases show methylation and potential response to temozolomide. The gene discussed is MGMT; the disease is central nervous system cancer.